Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Barostim Neo for Heart Failure
NCT02627196Completed
- Sponsor
- CVRx
- Start
- Apr 2016
- Primary completion
- Oct 2023
- Countries
- 2
01
Overview
Randomised, open-label trial in heart failure (HF) (2 arms), sponsored by CVRx. Primary endpoints: Rate of Cardiovascular Mortality and Heart Failure Morbidity at 3.6 years, Major Adverse Neurological and Cardiovascular Events at 6 months and 3 more. Started Apr 2016; status: completed.
02
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT02627196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627196.